Intervention

Biopsy Procedure

ClinicalTrials.gov intervention label

Clinical trials56

Recruiting24

Common conditions25

Lead sponsors shown12

Clinical trials

56 shown

Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate CancerNCT07790718 · 2026-12-16

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerNCT07322341 · 2026-10-01

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNCT07012031 · 2026-06-17

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate CancerNCT07468903 · 2026-05-11

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialNCT07288034 · 2026-04-08

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung CancerNCT07017829 · 2026-04-01

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerNCT07423585 · 2026-03-20

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerNCT07323641 · 2026-02-19

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerNCT07112053 · 2025-11-17

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerNCT06287775 · 2025-04-08

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialNCT06184750 · 2024-09-27

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate CancerNCT06145633 · 2024-09-18

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO TrialNCT06022822 · 2024-09-12

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA StudyNCT06039371 · 2024-05-21

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNCT05372640 · 2023-08-10

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast CancerNCT05422794 · 2023-05-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerNCT05111561 · 2022-08-02

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 · 2022-06-09

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerNCT04329065 · 2022-04-20

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 · 2021-04-13

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In SituNCT04144023 · 2019-06-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisNCT07578116 · 2027-03-09

NOT_YET_RECRUITING

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate CancerNCT07769372 · 2027-01-01

NOT_YET_RECRUITING

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE TrialNCT07590583 · 2026-12-19

NOT_YET_RECRUITING

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNCT07860554 · 2026-11-02

NOT_YET_RECRUITING

IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate CancerNCT07803653 · 2026-10-31

NOT_YET_RECRUITING

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")NCT07649304 · 2026-10-09

NOT_YET_RECRUITING

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE TrialNCT07526545 · 2026-09-01

NOT_YET_RECRUITING

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerNCT06590558 · 2025-08-04

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerNCT06528210 · 2025-04-16

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)NCT05554354 · 2024-09-13

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerNCT05828082 · 2023-10-16

ACTIVE_NOT_RECRUITING

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerNCT05673200 · 2023-09-25

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialNCT05554380 · 2023-09-22

ACTIVE_NOT_RECRUITING

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeNCT04929041 · 2022-10-07

ACTIVE_NOT_RECRUITING

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNCT05353439 · 2022-07-27

ACTIVE_NOT_RECRUITING

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerNCT04514497 · 2021-10-20

ACTIVE_NOT_RECRUITING

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNCT04704661 · 2021-08-09

ACTIVE_NOT_RECRUITING

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26

ACTIVE_NOT_RECRUITING

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerNCT04345913 · 2021-03-01

ACTIVE_NOT_RECRUITING

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive BiomarkerNCT04334941 · 2020-07-20

ACTIVE_NOT_RECRUITING

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerNCT03939897 · 2020-06-17

ACTIVE_NOT_RECRUITING

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the LungsNCT03896503 · 2019-12-30

ACTIVE_NOT_RECRUITING

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisNCT03317392 · 2019-02-04

ACTIVE_NOT_RECRUITING

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerNCT03600701 · 2018-11-29

ACTIVE_NOT_RECRUITING

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesNCT02971501 · 2018-06-27

ACTIVE_NOT_RECRUITING

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)NCT06385483 · 2018-02-28

ACTIVE_NOT_RECRUITING

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31

ACTIVE_NOT_RECRUITING

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerNCT02849496 · 2017-03-30

ACTIVE_NOT_RECRUITING

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)NCT06136897 · 2017-03-23

ACTIVE_NOT_RECRUITING

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerNCT02453620 · 2016-02-12

ACTIVE_NOT_RECRUITING

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17

ACTIVE_NOT_RECRUITING

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerNCT01116648 · 2010-04-14

ACTIVE_NOT_RECRUITING

Common conditions

Anatomic Stage IV Breast Cancer AJCC v818 Anatomic Stage III Breast Cancer AJCC v813 Stage IV Lung Cancer AJCC v810 Metastatic Malignant Solid Neoplasm9 Metastatic Hormone Receptor-Positive Breast Carcinoma7 Stage IVB Prostate Cancer AJCC v87 Unresectable Malignant Solid Neoplasm7 Advanced Malignant Solid Neoplasm6 Metastatic Breast Carcinoma6 Metastatic HER2-Negative Breast Carcinoma6 Metastatic Lung Non-Small Cell Carcinoma6 Metastatic Triple-Negative Breast Carcinoma6 Castration-Resistant Prostate Carcinoma5 Extensive Stage Lung Small Cell Carcinoma5 Stage III Lung Cancer AJCC v85 Unresectable Triple-Negative Breast Carcinoma5 Invasive Breast Carcinoma4 Metastatic Prostate Adenocarcinoma4 Refractory Malignant Solid Neoplasm4 Stage II Prostate Cancer AJCC v84 Locally Advanced Malignant Solid Neoplasm3 Lung Non-Small Cell Carcinoma3 Recurrent Breast Carcinoma3 Recurrent Lung Non-Small Cell Carcinoma3 Recurrent Malignant Solid Neoplasm3

Leading sponsors

National Cancer Institute (NCI)35 City of Hope Medical Center4 Fred Hutchinson Cancer Center4 University of Washington4 Jonsson Comprehensive Cancer Center2 Asrar Alahmadi1 Emory University1 Mayo Clinic1 OHSU Knight Cancer Institute1 Roswell Park Cancer Institute1 SWOG Cancer Research Network1 University of Michigan Rogel Cancer Center1

Trial status mix

RECRUITING24

ACTIVE_NOT_RECRUITING21

NOT_YET_RECRUITING7

WITHDRAWN2

SUSPENDED1

TERMINATED1

Phase mix

PHASE235

PHASE122

NA4

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.